A. Characteristics
- Solid, benign tumors of uterine smooth muscle
- Also called fibroids, myomas, or fibromyomas
- Most common masses of uterine origin
- Usually multiple nodules of different sizes
B. Occurrence
- Extremely common
- Over 20% of white females >30 years
- About 50% of black females >30 years
- Timing
- Rare before puberty
- Very common during childbearing years
- Rarely grow following menopause
- Organ Involvement
- Uterus most common
- Fallopian Tubes
- Vagina
- Ligaments (uterosacral, round)
- Vulva, gastrointestinal Tract
- ~30% of hysterectomies are performed due to symptomatic uterine fibroids
- Cowden Disease [1]
- Hamartomatous polyposis syndrome with colon cancer
- Uterine leiomyomas are common
- Due to mutations in PTEN gene on chromosome 10q
C. Pathology
- Initially, these are localized proliferations of smooth muscle
- With progression of growth, fibrous material is added
- These more advanced growths are called fibromyoma (fibroid)
- Growth is nearly always dependent on estrogens
- Distinct proliferative zones lead to differential growth rates causing multinodular uterus
- Frequently associated with polyps and endometrial hyperplasia
- Stromal Leiomyomatosis
- Global or symmetric enlargement of entire uterus
- Collagenous infiltration with whirling bundles of smooth muscle cells
- Multinodular studded uterus (both macro- and micronodular bundles)
- Degenerative Changes
- Occur frequently within the myoma
- Alterations in circulation - arterial or venous
- Infection - most comon with submucous fibroids, overlying endometrial tissue
- Malignant transformation (sarcomatous degeneration) is very rare
- Cystic and Hyaline Degeneration very common
- Necrosis - secondary to infection, infarction, or torsion
- Calcific Degeneration is usually end stage
D. Symptoms
- Most common is disturbance in menstrual period
- Initially, increase in amount of flow with normal cycle length maintained
- Late Changes
- Prolongation of Blood Flow (menorrhagia or hypermenorrhea)
- Appearance of Intramenstrual Bleeding (Usually with submucous myoma)
- Anemia (with increased bleeding)
- Pain
- Usually with menstrual cycle (dysmenorrhea)
- Acute pain with fibroids usually due to either torsion or infarction
- Feeling of pelvic heaviness with large myomas
- Infertility
- Pregnancy Loss - often second trimester loss (spontaneous abortion)
E. Diagnosis
- Clinical Symptoms Suggestive of Fibroids (very common)
- Pelvic Ultrasound
F. Treatment
- Highly Dependent on symptoms
- Progesterones (usually with birth control pills)
- GnRH Agonist
- "Chemical" oopherectomy
- Leads to reduction in estrogen and progesterone levels
- Agents are used in the treatment of endometriosis as well
- Uterine Artery Embolization (UAE) [2]
- Alternative invasive technique for treating uterine fibroids
- Embolic agent of 500-700 µm in diameter is placed in the artery feeding the fibroid
- Hospitalization typically 1 day
- Repeat procedure in ~10% of patients within 1 year
- Major adverse events ~5%
- Improved short term but similar long term outcomes versus hysterectomy/myomectomy
- Increased need for repeat procedures versus surgery
- Surgical Resection
- Often preceded by dilatation and curatage to rule out occult endometrial lesions
- Indications for surgery are discussed below
- UAE is often chosen initially for treatment of symptomatic fibroids
- Surgery is more definitive treatment for fibroids, requiring less repeat procedures [2]
G. Indications For Surgery
- Pain -Degeneration, Torsion, Dysmenorrhea
- Bleeding - Increased blood loss (menorrhagia), anemia
- Size ->12 gestational weeks equivalent
- Pressure - Bladder (Urgency), Ureters (Hydronephrosis)
- Location - Submucous, Intraligamentous, Pedunculated
- Reproductive Disorders - Sterility, Recurrent Abortion or Prematurity
- Evidence of Malignant Transformation - abnormal "complex" ultrasound appearance
- May be removed alone without a hysterectomy to preserve fertility
- About 30% of hysterectomies are performed due to uterine fibroids
References
- Ivanovich JL, Read TE, Ciske DJ, et al. 1999. Am J Med. 107(1):68

- REST Investigators. 2007. NEJM. 356(4):360
